Article (Scientific journals)
Médicaments anti-obésité : des déceptions aux espoirs.
Scheen, André; DE FLINES, Jenny; Paquot, Nicolas
2023In Revue Médicale de Liège, 78 (3), p. 147-152
Editorial Reviewed verified by ORBi
 

Files


Full Text
AJ-Scheen_2023_78_3_0 medic anti obesite.pdf
Author postprint (289.88 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anti-Obesity Agents; Glucagon-Like Peptide 1; IY9XDZ35W2 (Glucose); Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Humans; Anti-Obesity Agents/pharmacology/therapeutic use; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1/pharmacology/therapeutic use; Obesity/drug therapy; Glucose/therapeutic use; Glucagon-Like Peptide-1 Receptor/agonists; Hypoglycemic Agents/therapeutic use; Anorectic drugs; Gastrointestinal peptides; Glucagon-like peptide-1; Obesity; Pharmacotherapy; Safety
Abstract :
[en] Both physicians and patients dream of an efficacious and safe pharmacological approach to treat obesity. Unfortunately, most anti-obesity drugs prescribed since the fifties were associated with an unfavourable risk profile that led to numerous withdrawals. Medications issued from pharmaco-chemistry that mainly target brain amines to reduce appetite have been abandoned because of potential cardiovascular and neuropsychiatric toxicities. More recently, biological medications emerged, especially GLP-1 (Glucagon-Like Peptide-1) receptor agonists, well-known to manage type 2 diabetes and now recommended at higher doses for the treatment of obesity (liraglutide, semaglutide). A dual agonist that targets both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors (tirzepatide) appears to be even more potent as glucose-lowering agent and is currently tested as an anti-obesity agent. Many other pharmacological approaches are currently investigated but they should not mask the importance of life-style measurements.
Disciplines :
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de Diabétologie, Nutrition et Maladies métaboliques, Département de
DE FLINES, Jenny ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de Diabétologie, Nutrition et Maladies métaboliques, Département de
Paquot, Nicolas ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de Diabétologie, Nutrition et Maladies métaboliques, Département de
Language :
French
Title :
Médicaments anti-obésité : des déceptions aux espoirs.
Alternative titles :
[en] Anti-obesity drugs : from previous disappointments to new hopes.
Publication date :
March 2023
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Be
Volume :
78
Issue :
3
Pages :
147-152
Peer reviewed :
Editorial Reviewed verified by ORBi
Available on ORBi :
since 05 June 2023

Statistics


Number of views
67 (7 by ULiège)
Number of downloads
5 (1 by ULiège)

Scopus citations®
 
1
Scopus citations®
without self-citations
1

Bibliography


Similar publications



Contact ORBi